Ozmosi | Afluria Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Afluria

Pronounced as: uh-FLOOR-ee-uh

Alternative Names: Afluria
Clinical Status: Active
Latest Update: 2025-09-08
Latest Update Note: News Article

Product Description

AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. (Sourced from: https://www.fda.gov/vaccines-blood-biologics/vaccines/afluria-quadrivalent-afluria-quadrivalent-southern-hemisphere)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Intramuscular

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Chile | Colombia | Croatia | Germany | Italy | Korea | New Zealand | Portugal | Spain

Approved Indications: None

Known Adverse Events: None

Company: Seqirus
Company Location: Eastern America
Company Founding Year: 2015
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Afluria

Countries in Clinic: Australia

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Lupus Erythematosus, Systemic

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

ACTRN12623000397617

TWIRL

P2

Recruiting

Lupus Erythematosus, Systemic

2024-08-31

2026-02-15